Jeanna M. Wheeler

Jeanna M. Wheeler

Auto-generated profile, based on publicly available information

Jeanna M. Wheeler

Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2010 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
BKBrian C. Kraemer
Brian C. Kraemer
TSTheresa Schuck
Theresa Schuck
JWJeanna M. Wheeler
Jeanna M. Wheeler
LRLinda C. Robinson
Linda C. Robinson
JTJohn Q. Trojanowski
John Q. Trojanowski
GSGerard D. Schellenberg
Gerard D. Schellenberg

1 November 2006 in Genetics
Verified
Journal Article
Closed access
JWJeanna M Wheeler
Jeanna M Wheeler
JTJames H Thomas
James H Thomas
Organisms exposed to the damaging effects of high osmolarity accumulate solutes to increase cytoplasmic osmolarity. Yeast accumulates glycerol in response to osmotic stress, activated primarily by MAP kinase Hog1 signaling. A pathway regulated by protein kinase C (PKC1) also responds to changes in osmolarity and cell wall integrity. C. elegans accumulates glycerol when exposed to high osmolarity, but the molecular pathways responsible for this are not well understood. We report the identification of two genes, osm-7 and osm-11, which are related members of a novel gene family. Mutations in either gene lead to high internal levels of glycerol and cause an osmotic resistance phenotype (Osr). These mutants also have an altered defecation rhythm (Dec). Mutations in cuticle collagen genes dpy-2, dpy-7, and dpy-10 cause a similar Osr Dec phenotype. osm-7 is expressed in the hypodermis and may be secreted. We hypothesize that osm-7 and osm-11 interact with the cuticle, and disruption of the cuticle causes activation of signaling pathways that increase glycerol production. The phenotypes of osm-7 are not suppressed by mutations in MAP kinase or PKC pathways, suggesting that C. elegans uses signaling pathways different from yeast to mount a response to osmotic stress.

9 November 2009 in Genes, Brain and Behavior
Verified
Journal Article
Open access
PDF file
JWJ. M. Wheeler
J. M. Wheeler
CRC. Reed
C. Reed
SBS. Burkhart‐Kasch
S. Burkhart‐Kasch
NLN. Li
N. Li
CCC. L. Cunningham
C. L. Cunningham
Tamara J. PhillipsTamara J. Phillips
Tamara J. Phillips
Improved prevention and treatment of drug addiction will require deeper understanding of genetic factors contributing to susceptibility to excessive drug use. Intravenous operant self‐administration methods have greatly advanced understanding of behavioral traits related to addiction. However, these methods are not suitable for large‐scale genetic experiments in mice. Selective breeding of mice can aggregate ‘addiction alleles' in a model that has the potential to identify coordinated effects of multiple genes. We produced mouse lines that orally self‐administer high (MAHDR) or low (MALDR) amounts of methamphetamine, representing the first demonstration of selective breeding for self‐administration of any psychostimulant drug. Conditioned place preference and taste aversion results indicate that MAHDR mice are relatively more sensitive to the rewarding effects and less sensitive to the aversive effects of methamphetamine, compared to MALDR mice. These results validate the oral route of self‐administration for investigation of the motivational effects of methamphetamine and provide a viable alternative to intravenous self‐administration procedures. Gene expression results for a subset of genes relevant to addiction‐related processes suggest differential regulation by methamphetamine of apoptosis and immune pathways in the nucleus accumbens of MAHDR and MALDR mice. In each line, methamphetamine reduced an allostatic state by bringing gene expression back toward ‘normal’ levels. Genes differentially expressed in the drug‐naï ve state, including Slc6a4 (serotonin transporter), Htr3a (serotonin receptor 3A), Rela [nuclear factor κB (NFκB)] and Fos (cFos), represent candidates whose expression levels may predict methamphetamine consumption and susceptibility to methamphetamine reward and aversion.

1 March 2013 in Biological Psychiatry
Verified
Journal Article
Closed access
AMAllyson V. McCormick
Allyson V. McCormick
JWJeanna M. Wheeler
Jeanna M. Wheeler
CGChris R. Guthrie
Chris R. Guthrie
NLNicole F. Liachko
Nicole F. Liachko
BKBrian C. Kraemer
Brian C. Kraemer

1 January 2008 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
Tamara J. PhillipsTamara J. Phillips
Tamara J. Phillips
HKHelen Kamens
Helen Kamens
JWJeanna M. Wheeler
Jeanna M. Wheeler

18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JWJeanna M. Wheeler
Jeanna M. Wheeler
PMPamela McMillan
Pamela McMillan
TSTimothy J. Strovas
Timothy J. Strovas
NLNicole F. Liachko
Nicole F. Liachko
AAAlexandre Amlie-Wolf
Alexandre Amlie-Wolf
BKBrian Kraemer
Brian Kraemer
Brain lesions composed of pathological tau help to drive neurodegeneration in Alzheimer’s disease (AD) and related tauopathies. Here, we identified the mammalian suppressor of tauopathy 2 (MSUT2) gene as a modifier of susceptibility to tau toxicity in two mouse models of tauopathy. Transgenic PS19 mice overexpressing tau, a model of AD, and lacking the Msut2 gene exhibited decreased learning and memory deficits, reduced neurodegeneration, and reduced accumulation of pathological tau compared to PS19 tau transgenic mice expressing Msut2. Conversely, Msut2 overexpression in 4RTauTg2652 tau transgenic mice increased pathological tau deposition and promoted the neuroinflammatory response to pathological tau. MSUT2 is a poly(A) RNA binding protein that antagonizes the canonical nuclear poly(A) binding protein PABPN1. In individuals with AD, MSUT2 abundance in postmortem brain tissue predicted an earlier age of disease onset. Postmortem AD brain tissue samples with normal amounts of MSUT2 showed elevated neuroinflammation associated with tau pathology. We observed co-depletion of MSUT2 and PABPN1 in postmortem brain samples from a subset of AD cases with higher tau burden and increased neuronal loss. This suggested that MSUT2 and PABPN1 may act together in a macromolecular complex bound to poly(A) RNA. Although MSUT2 and PABPN1 had opposing effects on both tau aggregation and poly(A) RNA tail length, we found that increased poly(A) tail length did not ameliorate tauopathy, implicating other functions of the MSUT2/PABPN1 complex in tau proteostasis. Our findings implicate poly(A) RNA binding proteins both as modulators of pathological tau toxicity in AD and as potential molecular targets for interventions to slow neurodegeneration in tauopathies.